We also expect the facilities to support clinical trials and potential commercialization of our other eACT-based product candidates, including both chimeric antigen receptor and T-cell receptor-based product candidates." "We are committed to the rapid advancement of KTE-C19, which has the potential to address the significant, unmet needs of patients with aggressive, refractory B cell lymphomas and leukemias," said Arie Belldegrun, Kite Pharma's president and CEO, in a press release. "We are initiating pivotal studies for KTE-C19 in multiple indications and believe our new facilities will help ensure the timely completion of these studies as well as our commercial launch. The two facilities will support the planned clinical trials of Kite's product candidates and will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19, anticipated in 2017. Kite Pharma salary trends based on salaries posted anonymously by Kite Pharma employees. Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. 19, 2015 that it entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport.
Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT) products for the treatment of cancer, announced on Feb.
0 kommentar(er)
